Polyphenols in dementia: From molecular basis to clinical trials

Life Sciences

Volumn 161, Issue , 2016, Pages 69-77

  Molino, Silvia ^a   Dossena, Maurizia ^a   Buonocore, Daniela ^a   Ferrari, Federica ^a   Venturini, Letizia ^a   Ricevuti, Giovanni ^a   Verri, Manuela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Curcumin; Dementia; Epigallo catechin 3 gallate; Green tea catechins; Polyphenols; Resveratrol

Indexed keywords

CATECHIN; CHELATING AGENT; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METAL ION; POLYPHENOL DERIVATIVE; RESVERATROL; POLYPHENOL;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHELATION; DEMENTIA; DRUG BIOAVAILABILITY; DRUG MECHANISM; HUMAN; INTRACELLULAR SIGNALING; MEDLINE; NEUROPROTECTION; NONHUMAN; PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; ANIMAL; BIOAVAILABILITY; CLINICAL TRIAL (TOPIC);

ANIMALS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DEMENTIA; HUMANS; POLYPHENOLS;

EID: 84985034340     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.07.021     Document Type: Review

References (138)

1. [1] Prince, M., Albanese, E., Guerchet, M., Prina, M., World Alzheimer Report 2014 Dementia and Risk Reduction: An Analysis of Protective and Modifiable Factors. 2014.
2. [2] Cipriani, G., Lucetti, C., Carlesi, C., Danti, S., Nuti, A., Depression and dementia. A review. Eur. Geriatr. Med. 6 (2015), 479–486, 10.1016/j.eurger.2015.07.010.
3. [3] Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 9 (2013), 63–75, 10.1016/j.jalz.2012.11.007.
4. [4] United Nations, Department of Economic and Social Affairs, World Population Prospects : The 2015 Revision. Working Paper No. ESA/P/WP.241, 2015, 1–59 (doi:).
5. [5] OMS, Dementia: Public Health Priority. 2012 978 92 4 156445 8, 1–120.
6. [6] Sachdev, P.S., Blacker, D., Blazer, D.G., Ganguli, M., Jeste, D.V., Paulsen, J.S., et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat. Rev. Neurol. 10 (2014), 634–642, 10.1038/nrneurol.2014.181.
7. [7] Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., Alzheimer's disease. Lancet 377 (2011), 1019–1031, 10.1016/S0140-6736(10)61349-9.
8. [8] Dickstein, D.L., Walsh, J., Brautigam, H., Stockton, S.D. Jr., Gandy, S., Hof, P.R., Role of vascular risk factors andVascular dysfunction inAlzheimer's disease. Mt Sinai J. Med. 77 (2010), 82–102, 10.1002/MSJ.
9. [9] Eshkoor, S.A., Hamid, T.A., Mun, C.Y., Ng, C.K., Mild cognitive impairment and its management in older people. Clin. Interv. Aging 10 (2015), 687–693, 10.2147/CIA.S73922.
10. [10] Yaffe, K., Kanaya, A., Lindquist, K., Simonsick, E.M., Harris, T., Shorr, R.I., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (2004), 2237–2242, 10.1016/j.accreview.2004.12.135.
11. [11] Cherniack, E.P., A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br. J. Nutr. 108 (2012), 794–800, 10.1017/S0007114512000669.
12. [12] Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res. Rev. 9 (2010), 399–417, 10.1016/j.arr.2010.04.007.
13. [13] Iadecola, C., The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 120 (2010), 287–296, 10.1007/s00401-010-0718-6.
14. [14] Salomone, S., Caraci, F., Leggio, G.M., Fedotova, J., Drago, F., New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73 (2012), 504–517, 10.1111/j.1365-2125.2011.04134.x.
15. [15] Lista, S., Dubois, B., Hampel, H., Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. J. Nutr. Health Aging 19 (2015), 154–163, 10.1007/s12603-014-0515-3.
16. [16] Stough, C., Pase, M.P., Improving cognition in the elderly with nutritional supplements. Curr. Dir. Psychol. Sci. 24 (2015), 177–183, 10.1177/0963721414565449.
17. [17] Pase, M.P., Kean, J., Sarris, J., Neale, C., Scholey, A.B., Stough, C., The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J. Altern. Complement. Med. 18 (2012), 647–652, 10.1089/acm.2011.0367.
18. [18] A.S., Coley, N., Vaurs, C., Nutrition and cognition in aging adults. Clin. Geriatr. Med. 3 (2015), 453–464, 10.1016/j.cger.2015.04.008.
19. [19] Choi, D.Y., Lee, Y.J., Hong, J.T., Lee, H.J., Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res. Bull. 87 (2012), 144–153, 10.1016/j.brainresbull.2011.11.014.
20. [20] Manach, C., Scalbert, A., Morand, C., Rémésy, C., Jiménez, L., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79 (2004), 727–747.
21. [21] Tsao, R., Chemistry and biochemistry of dietary polyphenols. Nutrients 2 (2010), 1231–1246, 10.3390/nu2121231.
22. [22] Lakey-Beitia, J., Berrocal, R., Rao, K.S., Durant, A.a., Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways. Mol. Neurobiol. 51 (2015), 466–479, 10.1007/s12035-014-8722-9.
23. [23] Basli, A., Soulet, S., Chaher, N., Mérillon, J.-M., Chibane, M., Monti, J.-P., et al. Wine polyphenols: potential agents in neuroprotection. Oxidative Med. Cell. Longev., 2012, 2012, 805762, 10.1155/2012/805762.
24. [24] Afzal, M., Safer, A., Menon, M., Green tea polyphenols and their potential role in health and disease. Inflammopharmacology 23 (2015), 151–161, 10.1007/s10787-015-0236-1.
25. [25] Crozier, A., Jaganath, I.B., Clifford, M.N., Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 26 (2009), 965–1096, 10.1039/b802662a.
26. [26] Barzegar, A., Moosavi-Movahedi, A.A., Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One, 6, 2011, e26012, 10.1371/journal.pone.0026012.
27. [27] Gerszon, J., Rodacka, A., Puchała, M., Antioxidant properties of resveratrol and its protective effects in neurodegenerative diseases. Adv. Cell Biol. 4 (2014), 97–117, 10.2478/acb-2014-0006.
28. [28] Zaveri, N.T., Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci. 78 (2006), 2073–2080, 10.1016/j.lfs.2005.12.006.
29. [29] Bhardwaj, P., Khanna, D., Green tea catechins: defensive role in cardiovascular disorders. Chin. J. Nat. Med. 11 (2013), 345–353, 10.1016/S1875-5364(13)60051-5.
30. [30] Kang, K.W., Oh, S.J., Ryu, S.Y., Song, G.Y., Kim, B.H., Kang, J.S., et al. Evaluation of the total oxy-radical scavenging capacity of catechins isolated from green tea. Food Chem. 121 (2010), 1089–1094, 10.1016/j.foodchem.2010.01.055.
31. [31] Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J. Agric. Food Chem. 56 (2008), 4855–4873, 10.1021/jf0735073.
32. [32] Pandareesh, M.D., Mythri, R.B., Bharath, M.M.S., Bioavailability of dietary polyphenols: factors contributing to their clinical application in CNS diseases. Neurochem. Int. 89 (2015), 198–208, 10.1016/j.neuint.2015.07.003.
33. [33] Spencer, J.P.E., Metabolism of tea flavonoids in the gastrointestinal tract. J. Nutr. 133 (2003), 3255S–3261S.
34. [34] Barnes, S., Prasain, J., D'Alessandro, T., Arabshahi, A., Botting, N., Lila, M.A., et al. The metabolism and analysis of isoflavones and other dietary polyphenols in foods and biological systems. Food Funct. 2 (2011), 235–244, 10.1039/c1fo10025d.
35. [35] Manach, C., Williamson, G., Morand, C., Scalbert, A., Rémésy, C., Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81 (2005), 230S–242S.
36. [36] Garcea, G., Jones, D.J.L., Singh, R., Dennison, A.R., Farmer, P.B., Sharma, R.A., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 90 (2004), 1011–1015, 10.1038/sj.bjc.6601623.
37. [37] Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 (2007), 807–818, 10.1021/mp700113r.
38. [38] Wenzel, E., Soldo, T., Erbersdobler, H., Somoza, V., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49 (2005), 482–494, 10.1002/mnfr.200500003.
39. [39] Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J.E., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285 (2010), 9100–9113, 10.1074/jbc.M109.060061.
40. [40] Harada, M., Kan, Y., Naoki, H., Fukui, Y., Kageyama, N., Nakai, M., et al. Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin and (−)-epicatechin. Biosci. Biotechnol. Biochem. 63 (1999), 973–977, 10.1271/bbb.63.973.
41. [41] Landete, J.M., Updated knowledge about polyphenols: functions, bioavailability, metabolism, and health. Crit. Rev. Food Sci. Nutr. 52 (2012), 936–948, 10.1080/10408398.2010.513779.
42. [42] Abd El Mohsen, M.M., Kuhnle, G., Rechner, A.R., Schroeter, H., Rose, S., Jenner, P., et al. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med. 33 (2002), 1693–1702.
43. [43] Brasnyó, P., Molnár, G.A., Mohás, M., Markó, L., Laczy, B., Cseh, J., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106 (2011), 383–389, 10.1017/S0007114511000316.
44. [44] Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283 (2008), 20015–20026, 10.1074/jbc.M802187200.
45. [45] Li, M., Zhang, Z., Hill, D.L., Wang, H., Zhang, R., Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007), 1988–1996, 10.1158/0008-5472.CAN-06-3066.
46. [46] Heo, H.J., Kim, D.O., Shin, S.C., Kim, M.J., Kim, B.G., Shin, D.H., Effect of antioxidant flavanone, Naringenin, from citrus junos on neuroprotection. J. Agric. Food Chem. 52 (2004), 1520–1525, 10.1021/jf035079g.
47. [47] Scalbert, A., Manach, C., Morand, C., Rémésy, C., Jiménez, L., Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 45 (2005), 287–306, 10.1080/1040869059096.
48. [48] Prasad, S., Gupta, S.C., Tyagi, A.K., Aggarwal, B.B., Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol. Adv. 32 (2014), 1053–1064, 10.1016/j.biotechadv.2014.04.004.
49. [49] Al-Amiery, A.A., Kadhum, A.A.H., Obayes, H.R., Mohamad, A.B., Synthesis and antioxidant activities of novel 5-chlorocurcumin, complemented by semiempirical calculations. Bioinorg. Chem. Appl., 2013, 2013, 354982, 10.1155/2013/354982.
50. [50] Strasser, E.-M., Wessner, B., Manhart, N., Roth, E., The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochem. Pharmacol. 70 (2005), 552–559, 10.1016/j.bcp.2005.05.030.
51. [51] Nishinaka, T., Ichijo, Y., Ito, M., Kimura, M., Katsuyama, M., Iwata, K., et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol. Lett. 170 (2007), 238–247, 10.1016/j.toxlet.2007.03.011.
52. [52] Schipper, H.M., Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med. 37 (2004), 1995–2011, 10.1016/j.freeradbiomed.2004.09.015.
53. [53] Ishrat, T., Hoda, M.N., Khan, M.B., Yousuf, S., Ahmad, M., Khan, M.M., et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur. Neuropsychopharmacol. 19 (2009), 636–647, 10.1016/j.euroneuro.2009.02.002.
54. [54] Soares, D.G., Andreazza, A.C., Salvador, M., Sequestering ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and hydroxyl free radicals in chemical and biological systems. J. Agric. Food Chem. 51 (2003), 1077–1080, 10.1021/jf020864z.
55. [55] Li, H., Xia, N., Förstermann, U., Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26 (2012), 102–110, 10.1016/j.niox.2011.12.006.
56. [56] Heijnen, C.G., Haenen, G.R.M., van Acker, F.A., van der Vijgh, W.J., Bast, A., Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicol. in Vitro 15 (2001), 3–6, 10.1016/S0887-2333(00)00053-9.
57. [57] Yamabe, N., Yokozawa, T., Oya, T., Kim, M., Therapeutic potential of (−)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J. Pharmacol. Exp. Ther. 319 (2006), 228–236, 10.1124/jpet.106.107029.
58. [58] Haque, A.M., Hashimoto, M., Katakura, M., Hara, Y., Shido, O., Green tea catechins prevent cognitive deficits caused by Abeta1-40 in rats. J. Nutr. Biochem. 19 (2008), 619–626, 10.1016/j.jnutbio.2007.08.008.
59. [59] Levites, Y., Weinreb, O., Maor, G., Youdim, M.B., Mandel, S., Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78 (2001), 1073–1082.
60. [60] Skrzydlewska, E., Augustyniak, A., Michalak, K., Farbiszewski, R., Green tea supplementation in rats of different ages mitigates ethanol-induced changes in brain antioxidant abilities. Alcohol 37 (2005), 89–98, 10.1016/j.alcohol.2005.12.003.
61. [61] Srividhya, R., Jyothilakshmi, V., Arulmathi, K., Senthilkumaran, V., Kalaiselvi, P., Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (−)-epigallocatechin-3-gallate. Int. J. Dev. Neurosci. 26 (2008), 217–223, 10.1016/j.ijdevneu.2007.12.003.
62. [62] Assunção, M., Santos-Marques, M.J., Carvalho, F., Andrade, J.P., Green tea averts age-dependent decline of hippocampal signaling systems related to antioxidant defenses and survival. Free Radic. Biol. Med. 48 (2010), 831–838, 10.1016/j.freeradbiomed.2010.01.003.
63. [63] Himi, K.B., Hashimoto, M., Katakura, M., Haque, A.M., Hara, Y., Shido, O., Long-term administration of green tea catechins increases antioxidative actions and enhances neurogenesis in the hippocampus of rats. Curr. Top. Nutraceutical Res. 7 (2009), 131–140.
64. [64] Choi, Y.T., Jung, C.H., Lee, S.R., Bae, J.H., Baek, W.K., Suh, M.H., et al. The green tea polyphenol (−)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci. 70 (2001), 603–614.
65. [65] Santangelo, C., Varì, R., Scazzocchio, B., Di Benedetto, R., Filesi, C., Masella, R., Polyphenols, intracellular signalling and inflammation. Ann. Ist. Super. Sanita 43 (2007), 394–405.
66. [66] Esposito, E., Rotilio, D., Di Matteo, V., Di Giulio, C., Cacchio, M., Algeri, S., A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol. Aging 23 (2002), 719–735, 10.1016/S0197-4580(02)00078-7.
67. [67] Shakibaei, M., John, T., Schulze-Tanzil, G., Lehmann, I., Mobasheri, A., Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem. Pharmacol. 73 (2007), 1434–1445, 10.1016/j.bcp.2007.01.005.
68. [68] Li, X., Liu, X., Effect of curcumin on immune function of mice. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25 (2005), 137–140.
69. [69] Sandur, S.K., Ichikawa, H., Pandey, M.K., Kunnumakkara, A.B., Sung, B., Sethi, G., et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic. Biol. Med. 43 (2007), 568–580, 10.1016/j.freeradbiomed.2007.05.009.
70. [70] Capiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al-Abed, Y., Davies, P., et al. Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J. Neurochem. 120 (2012), 461–472, 10.1111/j.1471-4159.2011.07594.x.
71. [71] Relja, B., Tottel, E., Breig, L., Henrich, D., Schneider, H., Marzi, I., et al. Plant polyphenols attenuate hepatic injury after hemorrhage/resuscitation by inhibition of apoptosis, oxidative stress, and inflammation via NF-kappaB in rats. Eur. J. Nutr. 51 (2012), 311–321, 10.1007/s00394-011-0216-1.
72. [72] Ashafaq, M., Raza, S.S., Khan, M.M., Ahmad, A., Javed, H., Ahmad, M.E., et al. Catechin hydrate ameliorates redox imbalance and limits inflammatory response in focal cerebral ischemia. Neurochem. Res. 37 (2012), 1747–1760, 10.1007/s11064-012-0786-1.
73. [73] Kang, K.S., Wen, Y., Yamabe, N., Fukui, M., Bishop, S.C., Zhu, B.T., Dual beneficial effects of (−)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS One, 5, 2010, e11951, 10.1371/journal.pone.0011951.
74. [74] Farzaei, M.H., Rahimi, R., Abdollahi, M., The role of dietary polyphenols in the management of inflammatory bowel disease. Curr. Pharm. Biotechnol. 16 (2015), 196–210.
75. [75] Martin, D.A., Bolling, B.W., A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases. Food Funct. 6 (2015), 1773–1786, 10.1039/c5fo00202h.
76. [76] Biesalski, H.K., Polyphenols and inflammation: basic interactions. Curr. Opin. Clin. Nutr. Metab. Care. 10 (2007), 724–728, 10.1017/CBO9781107415324.004.
77. [77] González, R., Ballester, I., López-Posadas, R., Suárez, M.D., Zarzuelo, A., Martínez-Augustin, O., et al. Effects of flavonoids and other polyphenols on inflammation. Crit. Rev. Food Sci. Nutr. 51 (2011), 331–362, 10.1080/10408390903584094.
78. [78] Bhullar, K.S., Rupasinghe, H.P.V., Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxidative Med. Cell. Longev., 2013, 2013, 891748, 10.1155/2013/891748.
79. [79] Nemmar, A., Subramaniyan, D., Ali, B.H., Protective effect of curcumin on pulmonary and cardiovascular effects induced by repeated exposure to diesel exhaust particles in mice. PLoS One, 7, 2012, e39554, 10.1371/journal.pone.0039554.
80. [80] Reuter, S., Gupta, S.C., Park, B., Goel, A., Aggarwal, B.B., Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 6 (2011), 93–108, 10.1007/s12263-011-0222-1.
81. [81] Creţu, E., Trifan, A., Vasincu, A., Miron, A., Plant-derived anticancer agents - curcumin in cancer prevention and treatment. Rev. Med. Chir. Soc. Med. Nat. Iasi. 116 (2012), 1223–1229.
82. [82] Bi, X.L., Yang, J.Y., Dong, Y.X., Wang, J.M., Cui, Y.H., Ikeshima, T., et al. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol. 5 (2005), 185–193, 10.1016/j.intimp.2004.08.008.
83. [83] Rahman, I., Biswas, S.K., Kirkham, P.A., Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 72 (2006), 1439–1452, 10.1016/j.bcp.2006.07.004.
84. [84] Kang, O.-H., Jang, H.-J., Chae, H.-S., Oh, Y.-C., Choi, J.-G., Lee, Y.-S., et al. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol. Res. 59 (2009), 330–337, 10.1016/j.phrs.2009.01.009.
85. [85] Abraham, J., Johnson, R.W., Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res. 12 (2009), 445–453, 10.1089/rej.2009.0888.
86. [86] Crouvezier, S., Powell, B., Keir, D., Yaqoob, P., The effects of phenolic components of tea on the production of pro- and anti-inflammatory cytokines by human leukocytes in vitro. Cytokine 13 (2001), 280–286, 10.1006/cyto.2000.0837.
87. [87] Singh, R., Akhtar, N., Haqqi, T.M., Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. Life Sci., 87, 2010, 196, 10.1016/j.lfs.2010.06.009.
88. [88] Shen, C.-L., Yeh, J.K., Samathanam, C., Cao, J.J., Stoecker, B.J., Dagda, R.Y., et al. Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation. Osteoporos. Int. 22 (2011), 327–337, 10.1007/s00198-010-1209-2.
89. [89] Shen, C.-L., Samathanam, C., Graham, S., Dagda, R.Y., Chyu, M.-C., Dunn, D.M., Attenuate chronic inflammation-induced myocardial fibrosis in female rats. J. Med. Food 15 (2012), 269–277, 10.1089/jmf.2011.0163.
90. [90] Chen, B.-T., Li, W.-X., He, R.-R., Li, Y.-F., Tsoi, B., Zhai, Y.-J., et al. Anti-inflammatory effects of a polyphenols-rich extract from tea (Camellia sinensis) flowers in acute and chronic mice models. Oxidative Med. Cell. Longev. 2012 (2012), 1–7, 10.1155/2012/537923.
91. [91] Ahmed, S., Rahman, A., Hasnain, A., Lalonde, M., Goldberg, V.M., Haqqi, T.M., Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic. Biol. Med. 33 (2002), 1097–1105.
92. [92] Han, M.-K., Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp. Mol. Med. 35 (2003), 136–139, 10.1038/emm.2003.19.
93. [93] Li, R., Huang, Y.-G., Fang, D., Le, W.-D., (−)-epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J. Neurosci. Res. 78 (2004), 723–731, 10.1002/jnr.20315.
94. [94] Mandel, S.a., Amit, T., Weinreb, O., Youdim, M.B.H., Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 25 (2011), 187–208, 10.3233/JAD-2011-101803.
95. [95] Perron, N.R., Brumaghim, J.L., A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem. Biophys. 53 (2009), 75–100, 10.1007/s12013-009-9043-x.
96. [96] Schneider, S.A., Hardy, J., Bhatia, K.P., Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov. Disord. 27 (2012), 42–53, 10.1002/mds.23971.
97. [97] Dairam, A., Fogel, R., Daya, S., Limson, J.L., Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J. Agric. Food Chem. 56 (2008), 3350–3356, 10.1021/jf0734931.
98. [98] Du, X.-X., Xu, H.-M., Jiang, H., Song, N., Wang, J., Xie, J.-X., Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease. Neurosci. Bull. 28 (2012), 253–258, 10.1007/s12264-012-1238-2.
99. [99] Weinreb, O., Amit, T., Mandel, S., Youdim, M.B.H., Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. 4 (2009), 283–296, 10.1007/s12263-009-0143-4.
100. [100] Reznichenko, L., Amit, T., Zheng, H., Avramovich-Tirosh, Y., Youdim, M.B.H., Weinreb, O., et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (−)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 97 (2006), 527–536, 10.1111/j.1471-4159.2006.03770.x.
101. [101] Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J. Agric. Food Chem. 56 (2008), 4855–4873, 10.1021/jf0735073.
102. [102] Ramassamy, C., Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol. 545 (2006), 51–64, 10.1016/j.ejphar.2006.06.025.
103. [103] Bastianetto, S., Krantic, S., Quirion, R., Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev. Med. Chem. 8 (2008), 429–435.
104. [104] Ebrahimi, A., Schluesener, H., Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res. Rev. 11 (2012), 329–345, 10.1016/j.arr.2012.01.006.
105. [105] Zhang, C., Browne, A., Child, D., Tanzi, R.E., Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J. Biol. Chem. 285 (2010), 28472–28480, 10.1074/jbc.M110.133520.
106. [106] Pandey, N., Strider, J., Nolan, W.C., Yan, S.X., Galvin, J.E., Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 115 (2008), 479–489, 10.1007/s00401-007-0332-4.
107. [107] Daval, M., Bedrood, S., Gurlo, T., Huang, C.-J., Costes, S., Butler, P.C., et al. The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity. Amyloid 17 (2010), 118–128, 10.3109/13506129.2010.530008.
108. [108] Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., et al. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005), 5892–5901, 10.1074/jbc.M404751200.
109. [109] Kim, J., Lee, H.J., Lee, K.W., Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem. 112 (2010), 1415–1430, 10.1111/j.1471-4159.2009.06562.x.
110. [110] Rivière, C., Richard, T., Quentin, L., Krisa, S., Mérillon, J.-M., Monti, J.-P., Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg. Med. Chem. 15 (2007), 1160–1167, 10.1016/j.bmc.2006.09.069.
111. [111] Richard, T., Pawlus, A.D., Iglésias, M.-L., Pedrot, E., Waffo-Teguo, P., Mérillon, J.-M., et al. Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci. 1215 (2011), 103–108, 10.1111/j.1749-6632.2010.05865.x.
112. [112] Ngoungoure, V.L.N., Schluesener, J., Moundipa, P.F., Schluesener, H., Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases. Mol. Nutr. Food Res. 59 (2015), 8–20, 10.1002/mnfr.201400290.
113. [113] Mandel, S.A., Avramovich-Tirosh, Y., Reznichenko, L., Zheng, H., Weinreb, O., Amit, T., et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14 (2005), 46–60, 10.1159/000085385.
114. [114] Williams, R.J., Spencer, J.P.E., Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic. Biol. Med. 52 (2012), 35–45, 10.1016/j.freeradbiomed.2011.09.010.
115. [115] Meng, F., Abedini, A., Plesner, A., Verchere, C.B., Raleigh, D.P., The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49 (2010), 8127–8133, 10.1021/bi100939a.
116. [116] Bieschke, J., Russ, J., Friedrich, R.P., Ehrnhoefer, D.E., Wobst, H., Neugebauer, K., et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7710–7715, 10.1073/pnas.0910723107.
117. [117] Caruana, M., Högen, T., Levin, J., Hillmer, A., Giese, A., Vassallo, N., Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 585 (2011), 1113–1120, 10.1016/j.febslet.2011.03.046.
118. [118] Ferreira, N., Saraiva, M.J., Almeida, M.R., Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett. 585 (2011), 2424–2430, 10.1016/j.febslet.2011.06.030.
119. [119] Ringman, J.M., Frautschy, S.A., Teng, E., Begum, A.N., Bardens, J., Beigi, M., et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther., 4, 2012, 43, 10.1186/alzrt146.
120. [120] Baum, L., Lam, C.W.K., Cheung, S.K.-K., Kwok, T., Lui, V., Tsoh, J., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28 (2008), 110–113, 10.1097/jcp.0b013e318160862c.
121. [121] Turner, R.S., Resveratrol for Alzheimer's Disease. (NCT01504854), 2011.
122. [122] Sano, M., Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. (NCT00678431), 2008.
123. [123] Kerwin, D.R., Pilot Study of the Effects of Resveratrol Supplement in Mild-To-Moderate Alzheimer's Disease. (NCT00743743), 2008.
124. [124] BDPP, Treatment for Mild Cognitive Impairment (MCI) and Prediabetes. (NCT02502253), 2015.
125. [125] Wand, P.H., Brody, M.L., Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease. (NCT01716637), 2012.
126. [126] Floeel, A., Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI). 2015.
127. [127] Ide, K., Yamada, H., Takuma, N., Park, M., Wakamiya, N., Nakase, J., et al. Green tea consumption affects cognitive dysfunction in the elderly: a pilot study. Nutrients 6 (2014), 4032–4042, 10.3390/nu6104032.
128. [128] Poncha, F., Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease -. 2009.
129. [129] Frautschy, S.A., Curcumin and Yoga Therapy for those at Risk for Alzheimer's Disease. (NCT01811381), 2013.
130. [130] Small, G.W., 18-Month Study of Curcumin. (NCT01383161), 2011.
131. [131] Davis, M.C., Wynn, J.K., Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia. (NCT02104752), 2014.
132. [132] Patterson, J.C., Early Intervention in Mild Cognitive Impairment (MCI) with Curcumin + Bioperine. (NCT00595582), 2008.
133. [133] Allison, D.J., Ditor, D.S., Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial. J. Neuroinflammation, 12, 2015, 204, 10.1186/s12974-015-0425-2.
134. [134] Dow, C.T., Telomerase Activator and Retinal Amyloid. (NCT02530255), 2015.
135. [135] Gatson, J.W., Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers. (NCT01321151), 2011.
136. [136] Mochel, F., Resveratrol and Huntington Disease. (NCT02336633), 2015.
137. [137] Priller, J., Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study). (NCT01357681), 2011.
138. [138] Friedemann, P., Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer's Disease. (NCT00951834), 2009.